The Use of Flavonoids in Central Nervous System Disorders

被引:72
作者
Grosso, C. [1 ]
Valentao, P. [1 ]
Ferreres, F. [2 ]
Andrade, P. B. [1 ]
机构
[1] Univ Porto, REQUIMTE Lab Farmacognosia, Dept Quim, Fac Farm, P-4050313 Oporto, Portugal
[2] CEBAS CSIC, Dept Food Sci & Technol, Res Grp Qual Safety & Bioact Plant Foods, Murcia 30100, Spain
关键词
Alzheimer's disease; CNS; depression; epilepsy; Parkinson's disease; natural antioxidants; phenolic compounds; schizophrenia; ROTENONE-INDUCED APOPTOSIS; ST-JOHNS-WORT; ANTIDEPRESSANT-LIKE ACTIVITY; IMPROVES MEMORY IMPAIRMENT; BIOASSAY-GUIDED ISOLATION; GREEN TEA POLYPHENOLS; BLOOD-BRAIN-BARRIER; MONOAMINE-OXIDASE-B; OXIDATIVE STRESS; ALZHEIMERS-DISEASE;
D O I
10.2174/09298673113209990155
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neurodegenerative, neurological and psychiatric diseases are a group of pathologies with huge social and economic impacts. Since brain disorders continue to be pathological conditions for which corrective surgery cannot be widely used, treatments are based on drugs that only alleviate the symptoms. Despite all efforts in finding more efficient therapeutic agents, the requirement for neuroprotective drugs able to cross the blood-brain barrier (BBB) has been a hard challenge to overcome. Flavonoids are known by their antioxidant activities thus preventing oxidative stress, which is believe to be one of the causes of disorders affecting the central nervous system. Moreover, they can also modulate both enzymes and receptors activities, being regarded as multi-target botanical therapeutics or drugs. This review will give emphasis to the benefits of flavonoids found in the diet in the treatment of Alzheimer's disease, Parkinson's disease, epilepsy, depression, and schizophrenia. The antioxidant effect of several flavonoids, as well as their effects not related with antioxidant activity, in the above mentioned diseases will be reviewed. Aspects concerning structure-activity relationships, but also the bioavailability of these compounds in the brain will be referred.
引用
收藏
页码:4694 / 4719
页数:26
相关论文
共 181 条
[1]  
Adewusi EA, 2010, AFR J BIOTECHNOL, V9, P8257
[2]   Cholinesterase inhibitory constituents from Onosma hispida [J].
Ahmad, I ;
Anis, I ;
Malik, A ;
Nawaz, SA ;
Choudhary, MI .
CHEMICAL & PHARMACEUTICAL BULLETIN, 2003, 51 (04) :412-414
[3]   Structural requirements for the flavonoid fisetin in inhibiting fibril formation of amyloid β protein [J].
Akaishi, Tatsuhiro ;
Morimoto, Takeo ;
Shibao, Mami ;
Watanabe, Sayaka ;
Sakai-Kato, Kumiko ;
Utsunomiya-Tate, Naoko ;
Abe, Kazuho .
NEUROSCIENCE LETTERS, 2008, 444 (03) :280-285
[4]  
[Anonymous], 2017, The World Health Report 2017. Leishmaniose. In
[5]   Protective effect of quercetin in primary neurons against Aβ(1-42): relevance to Alzheimer's disease [J].
Ansari, Mubeen Ahmad ;
Abdul, Hafiz Mohammad ;
Joshi, Gururaj ;
Opii, Wycliffe O. ;
Butterfield, D. Allan .
JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2009, 20 (04) :269-275
[6]   Pharmacological profile of apigenin, a flavonoid isolated from Matricaria chamomilla [J].
Avallone, R ;
Zanoli, P ;
Puia, G ;
Kleinschnitz, M ;
Schreier, P ;
Baraldi, M .
BIOCHEMICAL PHARMACOLOGY, 2000, 59 (11) :1387-1394
[7]   The many faces of nitric oxide in schizophrenia. A review [J].
Bernstein, HG ;
Bogerts, B ;
Keilhoff, G .
SCHIZOPHRENIA RESEARCH, 2005, 78 (01) :69-86
[8]   Antioxidative enzyme activities and lipid peroxidation in major depression:: alterations by antidepressant treatments [J].
Bilici, M ;
Efe, H ;
Köroglu, MA ;
Uydu, HA ;
Bekaroglu, M ;
Deger, O .
JOURNAL OF AFFECTIVE DISORDERS, 2001, 64 (01) :43-51
[9]   Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes [J].
Bishnoi, Mahendra ;
Chopra, Kanwaljit ;
Kulkarni, Shrinivas K. .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 (05) :521-529
[10]   Schizophrenia: Redox Regulation and Volume Neurotransmission [J].
Bokkon, I. ;
Antal, I. .
CURRENT NEUROPHARMACOLOGY, 2011, 9 (02) :289-300